久久国产精品日本波多野结衣,欧美黑人巨大VIDEOS极品,永久黄网站色视频免费观看,日韩精品无码一区二区三区不卡

R&D overview company profiles

創(chuàng)新為先 科研卓著

Founded in 2010, Favord Institute for Biomedical Research covers 35,000 m2 and is equipped with all kinds of state-of-the-art facilities. With professionalism, expertise, compassion and dedication of all R&D personnel, the Institute has been bestowed honorary titles including China’s Excellent Innovation-oriented Chemical Pharmaceutical Enterprise Brand and Jiangsu Provincial Prize for Enterprise Technology Innovation

• R&D Input

  
  

  The company earmarks over 10% of its revenue every year for R&D, two times the amount of the industry’s average.

  
  

  
  

  R&D Achievements

  
  

  Over 100 projects are in development, including major science and technology projects at the national, provincial or municipal level. More than 100 patents have been granted.

• R&D Team

  
  

  There are over 400 R&D personnel, 70% or more of whom are doctors and masters. Additionally, 20-plus are with senior professional designations.

  
  

  
  

  Talent Recruitment

  
  

  The Institute is eager to bring in high-tech talents from home and abroad through multiple initiatives including“Make Enterprises Attractive to Doctors”, “333 High-end Talent Training Project”, “Innovative and Entrepreneurial Doctors” and “Six Talent Peaks Project in Jiangsu Province”.

• R&D Innovative Pipeline

  Small molecule innovative pipeline

  
  

  Clinical-stage programs

  
  

  NTQ1062, pan-AKT inhibitor, phase 2, HR+HER2- breast cancer.

  NTQ3617, MAT2A inhibitor, phase1, MTAP-/- tumor.

  NTQ5082, CFB inhibitor, phase 2, PNH & IgAN.

  
  

  Preclinical-stage programs

  
  

  NTQ6179, SSTR2 agonist, acromegaly & NETs.

  NTQ2204, lupus nephritis.

  NTQ2203 & NTQ2405, dermatosis.

  NTQ2301, IBD.

  
  

  Antibody innovative pipeline

  
  

  NTB001(Emicizumab Biosimilar), hemophilia A, IND.

  NTB003, IGF-1R mAb, thyroid-associated ophthalmopathy, IND.